2 Biotechs Battling Against Kidney Cancer
The treatment landscape for kidney cancer has undergone a significant shift in the last decade. Between 2006 and 2009, the U.S. Food and Drug Administration (FDA) approved six drugs for renal cell carcinoma (RCC), the most common form of kidney cancer. A new slate of targeted therapies and immunotherapies arrived on the scene in recent years. The latest approach, combining both types of drugs, has yielded better outcomes for patients than ever before.
Image source: Getty Images.
We'll get to the drugs, but first, a little about kidney cancer. According to the American Cancer Society, an estimated 74,000 people will be diagnosed with kidney cancer this year, making it a top 10 cancer in the U.S. RCC represents about 85% of all kidney cancers, and is most common in North America and Europe. Drug therapy is typically given for late stages of RCC where surgery is not an option, or following surgery to mop up any lingering cancer cells.
Source Fool.com